Coherus BioSciences Inc. (CHRS)
0.89
-0.03 (-2.81%)
At close: Mar 18, 2025, 3:59 PM
0.88
-0.94%
After-hours: Mar 18, 2025, 07:59 PM EDT
-2.81% (1D)
| Bid | 0.87 |
| Market Cap | 102.95M |
| Revenue (ttm) | 268.05M |
| Net Income (ttm) | 28.62M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 3.55 |
| Forward PE | -77.73 |
| Analyst | Buy |
| Ask | 0.89 |
| Volume | 1,577,031 |
| Avg. Volume (20D) | 2,188,262.4 |
| Open | 0.93 |
| Previous Close | 0.92 |
| Day's Range | 0.88 - 0.93 |
| 52-Week Range | 0.66 - 2.64 |
| Beta | 0.93 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 235
Stock Exchange NASDAQ
Ticker Symbol CHRS
Website https://www.coherus.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 688.02% from the latest price.
Stock ForecastsEarnings Surprise
Coherus BioSciences has released their quartely earnings
on Mar 10, 2025:
Next Earnings Release
Coherus BioSciences Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+24.82%
Coherus Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+13.29%
Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.
